Molecular Templates Inc MTEM

Healthcare Biotechnology

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).

NDAQ:MTEM - Post by User

Molecular Templates Inc

Bullboard Posts

Post by AviseAnalyticson Oct 05, 2021 8:25am

121 Views

Post# 33965985

4 BIOTECH STOCKS THAT WARRANT YOUR ATTENTION!

$MTEM $STRO $SNDX $KRYS

Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of these companies bring new and highly differentiated approaches, advanced scientific knowledge and a zeal for innovation to the table.

Our biotech picks this week are making strides in fields such as immune-oncology, hematologic disorders and dermatology and rare immune diseases. Some of these companies have entered into strategic collaborations with some major pharmaceutical companies and have upcoming catalysts in the form of data readouts, initiation of clinical trials and IND submission to look forward to.

Learn more

https://www.aviseanalytics.com/4-biotech-stocks-that-warrant-your-attention/

Bullboard Posts

Mining play provides exploration update